文献速递中医内科中药与中成药合理使用

血栓通注射液治疗急性脑梗死的疗效与安全性:临床证据及GRADE评价

Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment.
PubMed 文献 · Front Pharmacol · 2020-07-02

本研究通过Meta分析评估血栓通注射液联合常规治疗对急性脑梗死患者的疗效与安全性,纳入40项随机对照试验共3868例患者。结果显示联合治疗在总有效率、神经功能缺损评分、日常生活活动能力及炎症因子水平方面均优于常规治疗,不良反应无统计学差异,GRADE证据质量偏低。

要点

  • 血栓通联合常规治疗可提高急性脑梗死总有效率(RR=1.21)。
  • 联合治疗显著降低NIHSS评分并改善ADL评分。
  • 联合治疗降低hs-CRP和IL-6水平,不良反应无显著增加。

核心结论

  • Meta分析与GRADE评估有条件推荐血栓通联合常规治疗用于急性脑梗死,可提高总有效率、改善神经功能缺损和日常生活活动能力。
  • 联合治疗显著降低hs-CRP和IL-6水平,不良反应发生率与常规治疗无统计学差异。
  • GRADE评估提示该证据综合质量偏低。

研究设计与样本

  • 系统检索Cochrane Library、PubMed、Web of Science、EMBASE及四个中文医学数据库的随机对照试验。
  • 使用RevMan 5.3和STATA 16.0进行Meta分析,GRADEprofiler 3.6进行GRADE评估。
  • 共纳入40项研究,涉及3868例患者。

主要发现

  • 总有效率:血栓通联合常规治疗组优于常规治疗组(RR=1.21,95%CI=1.17-1.25,P<0.001)。
  • NIHSS评分:联合治疗组较对照组显著降低(WMD=-5.31,95%CI=-6.40至-4.22,P<0.001)。
  • ADL评分:联合治疗组显著优于对照组(WMD=12.51,95%CI=5.6-19.38,P<0.001)。
  • hs-CRP:联合治疗组降低更显著(WMD=-2.47,95%CI=-3.11至-1.82,P<0.001)。
  • IL-6:联合治疗组降低更显著(WMD=-13.66,95%CI=-17.80至-9.51,P<0.001)。

关键数值与推荐

  • GRADE评估综合证据质量偏低。
  • 总有效率RR=1.21(95%CI=1.17-1.25,P<0.001)。
  • NIHSS评分WMD=-5.31(95%CI=-6.40至-4.22,P<0.001)。
  • ADL评分WMD=12.51(95%CI=5.6-19.38,P<0.001)。
  • hs-CRP WMD=-2.47(95%CI=-3.11至-1.82,P<0.001),IL-6 WMD=-13.66(95%CI=-17.80至-9.51,P<0.001)。

临床怎么用

  • 在常规治疗基础上可考虑联合血栓通注射液以改善急性脑梗死患者神经功能与日常生活能力。
  • 联合治疗可能有助于降低炎症因子hs-CRP和IL-6水平。
  • 因证据质量偏低,临床决策需结合患者具体情况谨慎权衡。

局限性

  • 纳入研究的总体证据质量经GRADE评估为低。
  • 未报告具体不良反应类型及发生率数值。
  • 未报告各研究间的异质性及发表偏倚评估结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Xueshuantong injection (XST), a Chinese Medicine, is clinically effective in treating acute cerebral infarction (ACI). However, the meta-analysis of XST combined with conventional treatments (CTs) on ACI remain unexplored. The purpose of this study is to investigate the efficacy and safety of XST combined with CTs on patients with ACI. METHODS: Randomized controlled trials (RCTs) were screened from the Cochrane Library, PubMed, Web of Science, EMBASE, and four Chinese medical databases. The meta-analysis was performed using RevMan 5.3 and STATA 16.0. The GRADE assessment was performed by the GRADEprofiler (GRADEpro version: 3.6). The aggregate 95% confidence intervals (CIs) and relative risk (RR) estimates were calculated. RESULTS: Forty studies were included, involving a total of 3,868 patients. XST combined with CTs performed significantly better than CTs alone on the overall response rate (ORR) after treatment (RR = 1.21, 95% CI = 1.17-1.25, P < 0.001). There was no statistical differences in the incidence of adverse reactions between the experimental group (XST plus CTs) and control group (CTs alone). Groups treated with XST substantially decreased the National Institutes of Health Stroke Scale (NIHSS) score compared to the groups without XST (WMD = -5.31, 95% CI = -6.40 to -4.22, P < 0.001). Activities of daily living (ADL) scores were significantly better in the group treated with XST than CTs alone (WMD = 12.51, 95% CI = 5.6-19.38, P < 0.001). Patients who received XST combined with CTs showed significantly higher improvements in high-sensitivity C-reactive protein (hs-CRP) (WMD = -2.47, 95% CI = -3.11 to -1.82, P < 0.001) and interleukin 6 (IL-6) (WMD = -13.66, 95% CI = -17.80 to -9.51, P < 0.001) than those who received CTs alone. The GRADE assessment indicates that the comprehensive quality of this evidence is low. CONCLUSIONS: This meta-analysis and GRADE assessment conditionally recommend that XST combined with CTs can increase the overall response rate, ameliorate neurological deficit, and improve activities of daily living function more than CTs alone. A significant reduction in the hs-CRP and IL-6 levels were observed when XST was combined with CTs.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lyu J, Xie Y, Sun M, et al. Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment. Front Pharmacol. 2020. PMID: 32714181. doi:10.3389/fphar.2020.00822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。